firstwordpharma.com Open in urlscan Pro
104.18.31.185  Public Scan

Form analysis
0 forms found in the DOM

Text Content

You need to enable JavaScript to run this app.
Sign In
Register


Privacy

Terms of Use

Contact Us

Home

Pharma+

 * MyFW+ Stories
 * My Interests
 * My Saved Searches
 * Biosimilar
   IndexNEW

News

 * MyFW+ Stories
 * Top Stories
 * Product
 * Company
 * Regulatory
 * Condition
 * Business Area
 * Conference
 * People
 * All News

Insight, Analysis & Views

 * KOL Views
 * Physician Views
 * Spotlight On
 * ViewPoints
 * Friday Five
 * Vital Signs
 * FW in Conversation
 * All IAV

StoryWatch

 * Biosimilars
 * Coronavirus
 * Deals - Alliances - Financing
 * Emerging Markets
 * FDA AdCom Tracker
 * Gene/CAR-T Cell Therapy
 * Health Meets Tech
 * Latest Earnings Reports
 * Market Access Issues
 * Monkeypox in Focus
 * Orphan Drugs
 * Product Approvals
 * US Tackles Drug Prices

Events

Resources

More FW

 * My FirstWord
   ReportsBETA
 * FirstWord HealthTech
 * FirstAnswers
 * Advertise
 * About FirstWord


FIRSTWORD PHARMA


CONTINUE TO SITE

Redirect to site in 11 seconds

 * FirstWord HEALTHTECH

 * FirstWord REPORTS


FIRSTWORD PHARMA


 * Register
 * Sign In

Pharma+

News

Insight, Analysis & Views

StoryWatch

Events

Resources

More FW




BIONTECH TO INVEST IN AUTOLUS, GAINING CAR-T MANUFACTURING CAPACITY

The $200 million investment will allow BioNTech to expand its BNT211 programme
into trials for multiple cancer indications in "a cost-efficient way.”

1 hour ago


TOP STORIES

Top Story


ASTRAZENECA’S “CONSERVATIVE” GUIDANCE DISAPPOINTS, SHARES DIP 6%

Both sales and earnings are seen growing by a low double-digit to low teens
percentage, but some analysts pointed to less profit margin expansion than
expected.

2 hours ago
Top Story


ROCHE NABS FIRST GLOBAL APPROVAL FOR ITS SELF-INJECTED PNH TREATMENT

The authorisation allows patients in China to administer the anti-C5 recycling
monoclonal antibody crovalimab at home by subcutaneous self-injection every four
weeks.

4 hours ago
Top Story


REGENXBIO TARGETS ACCELERATED APPROVAL FOR MPS II GENE THERAPY

RGX-121 met the primary endpoint of the pivotal CAMPSIITE trial with an FDA
filing planned for the second half.

14 hours ago
Top Story


GILEAD AXES MAGROLIMAB DEVELOPMENT IN BLOOD CANCERS AFTER STUDIES SHOW MORTALITY
SIGNAL

The moves comes after another Phase III stoppage due to futility, as well as the
FDA upgrading a clinical hold on the anti-CD47 antibody.

21 hours ago
Top Story


SCION LIFE SCIENCES LAUNCHES WITH $310M TO BUILD NEW BIOTECHS

Scion is already deploying the cash to create four new biotechs.

24 hours ago

View More Top Stories




RECOMMENDED FOR YOU

Register in order to benefit from FirstWord Pharma's recommendation technology
helping you discover news and content of interest to you.


CONFERENCE NEWS

Press Release


DENALI THERAPEUTICS ANNOUNCES NEW DATA AND EXPANSION OF ITS BLOOD-BRAIN BARRIER
(BBB)-CROSSING ENZYME REPLACEMENT THERAPY PROGRAMS AT WORLDSYMPOSIUM™

  New data show additional improvement and stabilization in clinical outcomes in
MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label,
single-arm Phase 1/2 study; sustained ...

14 hours ago
Press Release


REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN
PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC
2024

RNS60 met its primary endpoints in RESCUE (safety and mortality) Clinically
relevant improvement with RNS60 on modified Rankin Scale (mRS), Barthel Index
and National Institute of Health Stroke Scale ...

14 hours ago
Press Release


DELTA-FLY PHARMA INC.: ABSTRACTS SUBMISSION FOR PHASE I CLINICAL TRIAL OF
DFP-14927 TO 2024 ASCO ANNUAL MEETING

 TOKUSHIMA, Japan--(BUSINESS WIRE)-- Following the previous information on Jan.
5th. in 2024, we are excited to share our latest development status.A Phase I
clinical dose-finding study of DFP-14927 i...

15 hours ago
Press Release


BLOOD THINNERS ADDED TO CLOT-BUSTING MEDICATION DID NOT IMPROVE STROKE OUTCOMES

Research Highlights: Although giving blood thinners along with clot-busting
medication may help in treating heart attacks, it did not improve 90-day
outcomes in people with clot-caused strokes. Enrol...

17 hours ago
Press Release


BIOMARIN TO PRESENT ROCTAVIAN™ (VALOCTOCOGENE ROXAPARVOVEC-RVOX) DATA
HIGHLIGHTING LONG-TERM DURABILITY AT 2024 EUROPEAN ASSOCIATION FOR HAEMOPHILIA
AND ALLIED DISORDERS (EAHAD) CONGRESS

 New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic
Benefit for Adults with Severe Hemophilia ASAN RAFAEL, Calif., Feb. 6, 2024
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasd...

40 hours ago

View More Conference News


RECENT REPORTS

FWReports


HEAD & NECK SQUAMOUS CELL CARCINOMA -- KOL INSIGHT

Despite the failure of the Merck Group/Pfizer’s JAVELIN 100 trial of Bavencio
KOLs remain optimistic that the integration of PD-1/L1 inhibitors into LA-HNSCC
could constitute a major advance – why? Wh...

March 11, 2022
FWReports


HEAD & NECK SQUAMOUS CELL CARCINOMA -- KOL INSIGHT -- REPORT HIGHLIGHTS

Despite the failure of the Merck Group/Pfizer’s JAVELIN 100 trial of Bavencio
KOLs remain optimistic that the integration of PD-1/L1 inhibitors into LA-HNSCC
could constitute a major advance – why? Wh...

March 11, 2022
FWReports


RHEUMATOID ARTHRITIS -- KOL INSIGHT

KOLs report that prescribing of anti-TNF therapies such as Pfizer/Amgen’s Enbrel
and AbbVie’s Humira has increased following strict safety warnings regarding JAK
inhibitors. What are the implications ...

March 03, 2022
FWReports


METAVERSE INNOVATIONS IN HEALTHCARE

How will the metaverse change pharma’s business? The metaverse represents a
shared existence in a virtual space and utilises a range of technologies from
augmented reality, virtual reality, and haptic...

March 03, 2022
FWReports


REGULATING DIGITAL HEALTH

Successfully navigate the evolving digital health regulatory environment In
response to the rapid pandemic-driven expansion of digital health, regulators
have been spurred to develop new frameworks a...

February 25, 2022

View More Reports


INSIGHT, ANALYSIS & VIEWS

Spotlight OnPLUS


SPOTLIGHT ON: AMGEN’S EARLY AMG 133 DATA SCORE ANOTHER POINT FOR GIP AGONISM IN
OBESITY

Vital SignsPLUS


VITAL SIGNS: CAN BLENREP TAKE ON TECVAYLI?

ViewPointsPLUS


VIEWPOINTS: LARGE LANGUAGE MODELS CAN BE GAME-CHANGING - BUT DATA QUALITY IS
CRITICAL

Spotlight OnPLUS


SPOTLIGHT ON: ASTRAZENECA, AMGEN’S TEZSPIRE GAINS GROUND IN US ASTHMA MARKET

Physician Views


PHYSICIAN VIEWS PREVIEW: BENCHMARKING A MILESTONE IN MEDICINE — CASGEVY AND
LYFGENIA IN SICKLE CELL DISEASE


View More Insight, Analysis & Views



 * FirstWord HEALTHTECH

 * FirstWord REPORTS

© 2024 FirstWord. All rights reserved
|
1140 Avenue of the Americas, 14th Floor, New York, NY 10036
About FirstWord|
Advertise With Us|
Contact Us|
Terms of Use|
Privacy Policy